Impact of diastolic dysfunction in patients with preserved ejection fraction undergoing permanent cardiac pacemaker placement

Abstract

Background

Chronic right-ventricular (RV) pacing can exacerbate heart failure in patients with a low ejection fraction (EF). There is little information on the effects of diastolic dysfunction (DD) in patients with preserved EF undergoing permanent pacemaker (PPM) placement. We aimed to investigate the clinical outcomes in these patients.

Methods

This multicenter, retrospective analysis of PPM use in Chonnam, South Korea, included all patients with preserved EF undergoing transvenous PPM implantation for atrioventricular blockage from 2017 to 2019. Patients were divided into two groups according to DD, which were assessed by including mitral flow velocities (E′ velocity, E/E′ ratio), peak velocity of the tricuspid regurgitant, and left atrial maximum volume index. Composite outcomes were defined as (1) cardiovascular death, and (2) hospitalization by heart failure during the follow-up period.

Results

One hundred sixty-seven patients (66 men; overall mean age, 75.3 ± 11.9 years) were divided into two groups: 125 normal versus 42 DD. Compared with normal subjects, the DD group included older patients (mean age, 79.1 ± 9.9 vs. 74.0 ± 12.3; p = 0.016), and had longer paced QTc interval (pQTc, 168.5 ± 20.1 vs. 159.1 ± 16.3 ms; p < 0.001). Fifteen patients were hospitalized and two died. In a Cox proportional regression analysis, DD (hazard ratio [HR], 7.343; 95% confidence interval [CI], 2.035–26.494; p = 0.002) and pQRSd (HR, 1.046; 95% CI, 1.004–1.091; p = 0.033) were independent predictors of composite outcomes.

Conclusion

In patients with DD, RV pacing raised the risk of pacing-induced heart failure despite preserved left-ventricular function. Thus, patients with DD should be monitored intensively.

Introduction

Chronic right-ventricular (RV) pacing can cause or worsen heart failure and increase cardiac mortality in patients with a low cardiac ejection fraction (EF) [1,2,3,4]. Therefore, physiologic interventions such as biventricular pacing were recommended in patients with reduced EF in need of ventricular pacing [5, 6]. However, it is controversial as to whether RV pacing is effective in patients with a preserved EF [7, 8]. Chronic RV pacing has shown heterogeneous clinical outcomes in those patients. In addition, the impact of RV pacing on clinical outcomes in patients with and without diastolic dysfunction (DD) has not been explored. We aimed to investigate the clinical outcomes during a long-term follow-up among patients undergoing permanent pacemaker (PPM) placement according to the presence or absence of DD.

Methods

Study population

This was a multicenter, retrospective analysis of PPM use from two tertiary centers in Gwang Ju, South Korea. All patients aged over 18 years undergoing de novo transvenous pacemaker implantation for a persistent atrioventricular block at Chosun University Hospital and Chonnam National University Hospital from January 2017 to December 2019 were recruited. Patients were included if they underwent dual-chamber PPM implantation, in whom the left-ventricular ejection fraction (LVEF) was ≥ 50% and ventricular pacing > 40%. The exclusion criteria were atrial fibrillation or flutter, severe valvular heart disease, cardiomyopathy, congenital heart disease, or terminal conditions with a life expectancy of < 1 year. The patients were divided into two groups according to their DD. Detailed histories and examinations of all patients were recorded at baseline. Their clinical characteristics, 12-lead electrocardiogram (ECG), and echocardiography parameters were evaluated. All patients enrolled in this study were seen as outpatients every 3–6 months and clinical follow-up was performed with respect to hospitalization or cardiac death caused by heart failure. The primary outcome was a composite of cardiovascular death (i.e., sudden death and pump failure death) or HF hospitalization during follow-up period. Pacing-induced cardiomyopathy (PICM) was defined as greater than 10% decrease in LVEF, with a resultant LVEF less than 50%, as previously reported [9].

PPM implantation

All patients received commercially available transvenous PPM systems approved by the Korean Food & Drug Administration. Active can devices and leads from three manufacturers (Abbott, St. Paul, MN, USA; Medtronic, Minneapolis, MN, USA; Boston, St Paul, MN, USA) were used. Pacemaker leads were inserted through the axillary vein using standard implantation techniques. Implantation procedures were performed through a pectoral approach. The RV leads were positioned in the RV apex or RV septum at the operator’s discretion. Electrical measurements were accepted with an R wave > 5 mV and a pacing threshold < 1.5 V. Once satisfactory testing results had been obtained, ventricular lead positions were confirmed by fluoroscopy in both left anterior oblique and right anterior oblique views (to cover the cardiac septum, not the free wall) and by ECG characteristics. Within 24 h, baseline ECG parameters were those acquired closest to PPM implantation; data were acquired at regular intervals (at least 6 months), and the pacing burdens (atrial and ventricular pacing percentages) were recorded at the time of follow-up.

Echocardiography

All patients underwent comprehensive echocardiography evaluations after PPM implantation within 7 days. Images were obtained with a standard ultrasound machine using a 2.5 MHz phased array transducer (Vivid 9; GE Vingmed, Horton, Norway). Standard techniques were used to obtain M mode, two-dimensional, and Doppler measurements following the American Society of Echocardiography guidelines. The LVEF was measured using the modified Simpson’s biplane method, and the LV stroke volume was calculated. Mitral inflow was assessed in an apical four-chamber view using pulsed wave Doppler ultrasonography. Diastolic functions were also evaluated using color tissue Doppler imaging (TDI) [10]. These were assessed by including mitral flow velocities, a mitral annular septal E′ velocity of < 7 cm/, an E/E′ ratio of > 14, peak velocity of the tricuspid regurgitant (TR) jet > 2.8 m/s and left atrial maximum volume index (LAVI) > 34 ml/m². LV DD was judged to be present if more than half of the available parameters met these cutoff values. Also, we compared clinical outcomes by the earlier 2009 DD criteria. DD was also graded as follows [11]. Normal pattern: E/A, > 0.8; deceleration time (DT), 160–240 ms; isovolumic relaxation time (IVRT), 70–90 ms; E/E′, < 10. Grade I: EA, < 0.8; DT, > 240 ms; IVRT, > 100 ms; E/ E′ < 10. Grade II: E/A, 0.8–2.0; DT, 160–240 ms; IVRT, 70–100 ms; E/E′, 10–14. Grade III: E/A, > 2; DT, < 160 ms; IVRT, < 70 ms; E/E′, > 14.

Statistical analysis

Baseline characteristics are summarized as the mean ± standard deviation for continuous variables, and as frequencies with percentages for categorical variables. We compared the results within a group by testing for normality with the Kolmogorov–Smirnov test. Comparisons between the two groups were analyzed by Student’s t test or the Mann–Whitney nonparametric U test for continuous variables, and the Chi squared test for categorical variables, as appropriate. A Cox proportional regression model was used to determine the predictors of composite clinical outcomes, and a receiver operating characteristic (ROC) curve was plotted to identify the cutoff values for the occurrence of composite clinical outcomes using the area under the curve (AUC) with Youden’s approach in Medcalc (v. 20.0; https://www.medcalc.org/calc/). All statistical tests were two-sided and were performed using IBM SPSS Statistics (v. 24.0; IBM Corp., Armonk, NY, USA). p values < 0.05 were considered significant and the results are presented as the hazard ratio (HR) and 95% confidence.

Results

Study population

Figure 1 shows the patient flow diagram for this study. Among all patients, 167 with atrioventricular block (66 men, 39.5%; overall mean age 75.3 ± 11.9 years) were included. They were divided into two groups: 42 with DD versus 125 normal. The participants’ baseline clinical characteristics are shown in Table 1. Patients in the DD group were older (79.1 ± 9.9 vs. 74.0 ± 12.3 y; p = 0.016). There were no significant differences in gender or cardiovascular risk factor (diabetes mellitus, hypertension, dyslipidemia, cerebrovascular accident, coronary artery disease). The LVEF was not different between the groups at baseline (58.1 ± 10.2 vs. 58.1 ± 8.9, p = 0.992). Diastolic function variables were greater in the DD group, as expected. Paced QRS duration (pQRSd) was not different between the two groups; however, the paced QTc (pQTc) interval was prolonged in the DD group (516.8 ± 39.3 in the DD vs. 498.3 ± 45.4 in the normal group; p < 0.001).

Fig. 1

Flowchart of study protocol

Table 1 Baseline characteristics

Device-related parameters

Table 2 lists the device-related characteristics. No complications occurred during PPM implantation. The average P and R wave amplitudes, pacing thresholds, and impedance values were not different between the groups. The percentage of ventricular pacing > 90% was not statistically different between groups and the pacing site was not significantly associated with DD.

Table 2 Device-related parameters

Clinical outcomes

The clinical outcomes are listed in Table 3. Over a median of 31-month follow-up, the overall incidence of PPM-induced heart failure was 10.1% (15 hospitalizations and two cardiac deaths). Their ejection fraction was 38.05 ± 7.65%, which were consistent with pacing-induced cardiomyopathy at follow-up echocardiography. More patients with DD were admitted to hospital for heart failure (31.0% vs. 3.2%; p = 0.001). Cox proportional regression analysis was applied to identify the predictors of composite outcomes (Table 4) (Fig. 2). The diastolic dysfunction (HR, 7.343; 95% CI, 2.035–26.494; p = 0.002) and paced QRS duration (pQRSd: HR, 1.046; 95% CI, 1.004–1.091; p = 0.033) were independent predictors of composite clinical outcomes. Most of the patients were classed as having Grade I DD (Fig. 3a) according to the 2009 guideline. On the other hand, the greater the number of DD variables (2016 guideline), the higher the probability of composite clinical outcomes (Fig. 3b). ROC curve analysis (AUC area, 0.721; 95% CI, 0.610–0.833; p = 0.004) showed that a pQRSd of 168 ms had a 75.0% sensitivity and a 64.2% specificity for predicting the occurrence of composite clinical outcomes (Fig. 4).

Table 3 Composite clinical outcomes

Table 4 Predictors of composite clinical outcomes using cox proportional hazard model

Fig. 2

Cox proportional hazard model showing the proportions of patients free from composite clinical outcomes associated with diastolic dysfunction (DD)

Fig. 3

Diastolic dysfunction (DD) and composite clinical outcomes. A. Most of the patients were classed as having Grade I DD according to the 2009 guidelines. B. The greater the number of DD variables, the higher the probability of composite clinical outcomes according to the revised 2016 guidelines

Fig. 4

Receiver operating characteristic curve (ROC) analysis. The AUC area of 0.721 (95% CI 0.610–0.833; p = 0.004) showed that a pQRSd of 168 ms had a 75.0% sensitivity and a 64.2% specificity for predicting the incidence of composite clinical outcomes

Discussion

Since the beginning of pacing therapy in 1958, the RV is still the established site for undergoing PPM insertion [1]. Although RV pacing can contract both ventricles relatively effectively, this could induce ventricular dyssynchrony and detrimental hemodynamic effects. In turn, this might lead to progressive adverse remodeling at cellular and heart chamber levels with resultant deterioration in ventricular function [12]. Chronic RV pacing can cause or worsen heart failure and increase cardiac mortality [1,2,3,4]. The adverse clinical outcomes of prolonged RV apical pacing in some patients are increasingly recognized, which ultimately might result in fatal pacing-induced cardiomyopathy, which occurred in 16.1% of patients in a study conducted in South Korea [13]. Here, the overall incidence of pacemaker-induced heart failure was 10.1% during a median of 31-month follow-up.

Earlier studies have shown that a lower EF is a statistically significant factor for the development of PICM [3, 4]. Physiologic pacing is recommended in patients with reduced EF and a high degree of atrioventricular blockage in need of ventricular pacing. However, this method is controversial in patients with preserved EF. One interesting finding of our study is that DD could affect pacemaker-induced heart failure in patients with preserved LV function. Diastolic function is an equally vital component of the cardiac cycle, which is closely linked with systolic function. It indicates a functional abnormality of diastolic relaxation-linked filling or distensibility of the LV, which reflects abnormal mechanical properties of this ventricle [14]. When DD already exists, the additional stress provoked by RV pacing might induce further functional abnormalities, such as electromechanical delay caused by a pacing-induced left bundle branch block pattern and regional perfusion defects [15]. Therefore, it is possible that RV pacing contributes to a further degree of LV systolic dysfunction and more clinical heart failure (HF).

In our study, DD was evaluated by four variables (E′, E/E′ ratio, LAVI, and TR velocity) as recommended by the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging guidelines, which are simpler and more practical indicators than the 2009 guidelines. In addition to mitral flow pattern and mitral annular velocity, the updated guidelines include left atrium chamber size and TR gradient, which predicting the risk of developing HF on long-term RV pacing in patients with preserved LV function in our study (Fig. 2). The greater the sum of DD variables, the higher the probability of pacemaker-induced HF (Fig. 3b). This is particularly relevant in the population paced for CAVB who are usually older and who will have an age-related decline in diastolic function. According to the 2009 guidelines, most of the elderly patients were assigned to Grade I DD, (Fig. 3a). However, in the revised 2016 guidelines, higher DD variables affect composite clinical outcomes adversely, so it is possible to identify high-risk patients.

In addition, the pQRSd is a known risk factor for pacemaker-induced HF [13, 16,17,18]. Therefore, patients with a longer pQRSd are at higher risk. Khurshid et al. also proposed that a pQRSd of 150 ms was a sensitive indicator for such HF [16]. In our study, ROC analysis showed that a pQRSd of 168 ms had a 75.0% sensitivity and a 64.2% specificity for predicting the occurrence of PPM-induced HF. These findings show that patients with a higher pQRSd (> 168 ms) must be monitored intensively with more periodic echocardiography. This modifiable factor helped to decrease the incidence of PPM-induced HF and efforts should be directed toward minimizing it, such as biventricular pacing and conduction system pacing. The use of biventricular pacing is well accepted for the treatment of patients with systolic HF and prolonged QRS duration, with several clinical trials performed over the past 20 years demonstrating improvements in morbidity and mortality [19]. Unfortunately, the effectiveness of CRT in patients with CAVB and preserved LV function is questionable [7]. Recently, utility of His-Purkinje system pacing including his bundle pacing and left bundle branch pacing was shown to preserve cardiac synchrony [20]. Theoretically, this will reduce the odds that dyssynchrony will occur. His bundle pacing may be beneficial in those with an anticipated high percent of RV pacing and possibly even those who have an indication for cardiac resynchronization therapy (CRT) such as a left bundle branch block [21, 22]. However, HBP is limited by poor ventricular sensing, elevated acute and chronic pacing thresholds necessitating lead reintervention and rapid battery replacement, and failure to reliably normalize the QRS complex in patients with bundle branch block [23]. On the contrary, left bundle branch pacing might be able to overcome more distal conduction disease. It is a feasible and effective method for left bundle branch block in patients with nonischemic cardiomyopathy [24]. However, long-term clinical outcomes of left bundle branch pacing are needed in future randomized clinical trials.

Limitations

This study included a relatively small number of patients in the two referral centers in South Korea, which might limit generalization of the results. First, the small study size and low incidence rate made it difficult to identify the real impact of DD. Second, the nonrandomized nature of the registry data could have resulted in selection bias. Because this was a multicenter observational registry, the influence of different physicians on clinical decision making might have also influenced the clinical variables associated with HF. Third, the primary outcome was a composite of cardiovascular (CV) death (i.e. ,sudden cardiac death and pump failure death) or HF hospitalization during follow-up period. Because follow-up echocardiography was not performed in all patients, we did not check the individual changes in patients’ LVEF. Also, 9 patients who were hospitalized or died from other causes (i.e., 2 sepsis, 1 pacemaker pocket infection, 1 leukemia, 1 lung cancer, 1 rectal cancer, 1 fracture of hand, and 2 coronary artery disease) were excluded from the outcome analysis.

Conclusions

In patients with DD, RV pacing raised the risk of pacing-induced HF during a median of 31 months of follow-up despite preserved LV function. Our results suggest that the patients with DD undergoing PPM placement should be monitored intensively.